Disclosure of HIV Status and Adherence to Daily Drug Regimens Among HIV-infected Children in Uganda

African Network for the Care of Children Affected by AIDS (2004). Handbook on paediatric AIDS in Africa.

Belzer, M. E., Fuchs, D. N., Luftman, G. S., & Tucker, D. J. (1999). Antiretroviral adherence issues among HIV-positive adolescents and young adults. Journal of Adolescent Health, 25, 316–319.

Blasini, I., Chantry, C., Cruz, C., Ortiz, L., Salabarria, I., Scalley, N., & Matos, B. (2004). Disclosure model for pediatric patients living with HIV in Puerto Rico: Design, implementation, and evaluation. Journal of Developmental and Behavioral Pediatrics, 25, 181–189.

Boni, S., Pontali, E., De, G. P., Pedemonte, P., & Bassetti, D. (2000). Compliance to combination antiretroviral therapy in HIV-1 infected children. International Journal of Antimicrobial Agents, 16, 371–372.

Chintu, C., Bhat, G. J., Walker, A. S., Mulenga, V., Sinyinza, F., Lishimpi, K., & Farrelly, L. (2004). Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): A double-blind randomised placebo-controlled trial. Lancet, 364, 1865–1871.

Elise, A., France, A. M., Louise, W. M., Bata, D., Francois, R., Roger, S., & Philippe, M. (2005). Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Cote d’Ivoire. Journal of Acquired Immune Deficiency Syndromes, 40, 498–500.

Fassinou, P., Elenga, N., Rouet, F., Laguide, R., Kouakoussui, K. A., Timite, M., & Blanche, S. (2004). Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d’Ivoire. AIDS, 18, 1905–1913.

Lester, P., Chesney, M., Cooke, M., Whalley, P., Perez, B., Petru, A., & Dorenbaum, A. (2002). Diagnostic disclosure to HIV-infected children: How parents decide when and what to tell. Clinical Child Psychology and Psychiatry, 7, 85–99.

Martinez, J., Bell, D., Camacho, R., Henry-Reid, L. M., Bell, M., Watson, C., & Rodriguez, F. (2000). Adherence to antiviral drug regimens in HIV-infected adolescent patients engaged in care in a comprehensive adolescent and young adult clinic. Journal of the National Medical Association, 92, 55–61.

Mehta, S., Moore, R. D., & Graham, N. M. (1997). Potential factors affecting adherence with HIV therapy [editorial]. AIDS, 11, 1665–1670.

Mermin, J., Lule, J., Ekwaru, J. P., Malamba, S., Downing, R., Ransom, R., & Kaharuza, F. (2004). Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4 cell count, and HIV viral load among persons with HIV in rural Uganda. Lancet, 364, 1428–1434.

Murphy, D. A., Sarr, M., Durako, S. J., Moscicki, A. B., Wilson, C. M., & Muenz, L. R. (2003). Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Archives of Pediatric Adolescent Medicine, 157, 249–255.

Murphy, D. A., Wilson, C. M., Durako, S. J., Muenz, L. R., & Belzer, M. (2001). Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care, 13, 27–40.

Reddington, C., Cohen, J., Baldillo, A., Toye, M., Smith, D., Kneut, C., & Demaria, A. (2000). Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatric Infectious Disease Journal, 19, 1148–1153.

Shingadia, D., Viani, R. M., Yogev, R., Binns, H., Dankner, W. M., Spector, S. A., & Chadwick, E. G. (2000). Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. Pediatrics, 105, E80.

Steele, R. G., Anderson, B., Rindel, B., Dreyer, M. L., Perrin, K., Christensen, R., & Tyc, V. (2001). Adherence to antiretroviral therapy among HIV-positive children: Examination of the role of caregiver health beliefs. AIDS Care, 13, 617–629.

Steele, R. G., & Grauer, D. (2003). Adherence to antiretroviral therapy for pediatric HIV infection: Review of the literature and recommendations for research. Clinical Child Family Psychology Review, 6, 17–30.

Temple, M. E., Koranyi, K. I., & Nahata, M. C. (2001). The safety and antiviral effect of protease inhibitors in children. Pharmacotherapy, 21, 287–294.

UNAIDS. (2004). Report on the global HIV/AIDS epidemic: 4th global report. [Retrieved from: http://www.unaids.org/bangkok2004/GAR2004_pdf/UNAIDSGlobalReport2004_en.pdf].

van Dyke, R. B., Lee, S., Johnson, G. M., Wiznia, A., Mohan, K., Stanley, K., & Morse, E. V. (2002). Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics, 109, 1–7.

van Rossum, A. M., Fraaij, P. L., & de Groot, R. (2002). Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infectious Disease, 2, 93–102.

Watson, D. C., & Farley, J. J. (1999). Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatric Infectious Disease Journal, 18, 682–689.

Waugh, S. (2003). Parental views on disclosure of diagnosis to their HIV-positive children. AIDS Care, 15, 169–176.

Williams A., & Friedland, G. (1997). Adherence, compliance, and HAART. AIDS Clinical Care, 9, 51–54, 58.

World Health Organization. (2006). Who expert consultation on cotrimoxazole prophylaxis in HIV infection. [Retrieved from: http://www.womenchildrenhiv.org].